Everything you need to write about Burna AI accurately.
Burna AI is the safety and data quality platform for clinical research, from early phase trials through postmarket surveillance. Fact sheet, boilerplate, founder bios, brand assets, speaking calendar, and a press contact who responds in one business day.
Boilerplate. Lift verbatim.
The paragraphs below are the canonical company descriptions. They are cleared for verbatim use in any article, press release, conference program, podcast intro, or analyst report. No permission required.
The canonical one-liner
Burna AI is the safety and data quality platform for clinical research, from early phase trials through postmarket surveillance.
Short boilerplate (45 words)
Burna AI is the safety and data quality platform for clinical research, from early phase trials through postmarket surveillance. The platform pairs CTCAE coding and grading, every grade traceable to the line in the medical record that produced it, with multi-drug attribution. Human-in-the-loop, always. CancerX member. FDA Emerging Drug Safety Technology Program application in review.
Long boilerplate (95 words)
Burna AI is the safety and data quality platform for clinical research, from early phase trials through postmarket surveillance. The proprietary Burna AI engine is a patented cascading constraint pipeline of twelve specialized agents that produces CTCAE coding, including TERM and CATEGORY, coupled with intelligence to support determination of Severity GRADE, with mandatory citation to source text. Burna serves cancer centers, pharma and biotech sponsors, and contract research organizations through a single platform with regional deployment across the US, UK, EU, APAC, and MENA. Founded in 2024 by Nnenna John. Headquartered in the United States.
Burna AI at a glance.
Two-column fact panel. For more depth or for any number not listed here, email press@burna.ai.
Founded
2024
Founder and CEO
Nnenna John
Advisors
25 across 5 councils (Clinical, Regulatory & Standards, Tech & Product, Commercial, Brand & Adoption)
Memberships
CancerX (HHS Cancer Moonshot Initiative)
Product lines
CTCAE AI (cancer centers, AMCs, CROs) and Protocol Safe (pharma sponsors)
Algorithms
WHO-UMC and Kramer causality attribution, both regulator-recognized by FDA, EMA, PMDA, MHRA
Headquarters
United States
Lead engineer and co-founder
Paschal Ezeugwu
Patents
Two filed on the cascading constraint pipeline
Regulatory
FDA Emerging Drug Safety Technology Program application in review
Coverage
850 CTCAE criteria (v5.0 and v6.0). 42 oncology regimen profiles.
Governance
Human-in-the-loop, always
Pre-cleared for editorial use.
Primary wordmark in horizontal and stacked lockups. Light, dark, and reversed variants. SVG, PNG (transparent), and PDF inside the press kit ZIP under /logos. High-resolution variants and any asset not listed here are available on request: press@burna.ai.
Burna AI
Wordmark · Light · SVG PNG PDF
Burna AI
Wordmark · Reversed · SVG PNG PDF
Press contact · press@burna.ai
Press inquiries, embargoed news, interview requests, and time-sensitive coverage. First response within one business day during standard cycles. Same-day for breaking news on request; include “Urgent” or “Embargoed” in the subject line.